LEXEO THERAPEUTICS, INC.

Press Releases Lexeo Therapeutics, Inc.

Equities

LXEO

US52886X1072

Real-time Estimate Cboe BZX Other stock markets 08:30:06 20/05/2024 pm IST			5-day change	1st Jan Change
13.97 ^USD	+0.87%		+2.95%	+4.02%

09/05	Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01/05	Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights	09/05	AQ
Lexeo Therapeutics to Participate in Upcoming Investor Conferences	07/05	AQ
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy	22/04	AQ
LEXEO THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR LX2006, AN AAV-BASED GENE THERAPY CANDIDATE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA CARDIOMYOPATHY	17/04	AQ
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy	16/04	AQ
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing	14/03	AQ
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	11/03	AQ
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing	11/03	AQ
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments	05/02	AQ
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	AQ
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)	18/12	AQ
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights	11/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW